Non Small Cell Lung Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024

DelveInsight's, "Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non Small Cell Lung Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Non Small Cell Lung Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Non Small Cell Lung Cancer Pipeline Report

* In September 2024:- AstraZeneca- A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
* In September 2024:- Novartis Pharmaceuticals- This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.
* DelveInsight's Non Small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Non Small Cell Lung Cancer treatment.
* The leading Non Small Cell Lung Cancer Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc., and others.
* Promising Non-Small Cell Lung Cancer Therapies such as Amivantamab, Lazertinib, Pemetrexed 500 mg, BPI-361175, AZD2936, Durvalumab (MEDI4736), Gemcitabine, Durvalumab, BLEX 404, and others.

Stay ahead with the most recent pipeline outlook for Non Small Cell Lung Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non Small Cell Lung Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Small-Cell Lung cancer (NSCLC) Emerging Drugs

* AMG 510: Amgen

AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.

* CMP 001: Cytos Biotechnology

CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.

Explore groundbreaking therapies and clinical trials in the Non Small Cell Lung Cancer Pipeline. Access DelveInsight's detailed report now! @ New Non Small Cell Lung Cancer Drugs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Subcutaneous
* Intravenous
* Oral
* Parenteral
* Intramuscular
* Molecule Type

Non Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Small molecules
* Peptides
* Polymer
* Gene Therapy
* Monoclonal antibodies
* Product Type

Unveil the future of Non Small Cell Lung Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non Small Cell Lung Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Non Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* Non Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc., and others.
* Non-Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, BPI-361175, AZD2936, Durvalumab (MEDI4736), Gemcitabine, Durvalumab, BLEX 404, and others.
* Non Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Non Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NSCLC Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NSCLC Companies, Key Products and Unmet Needs

Table of Content

* Introduction
* Executive Summary
* Non-Small-Cell Lung cancer (NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Late Stage Products (Pre Registration)
* AMG 510: Amgen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CMP 001: Cytos Biotechnology
* Drug profiles in the detailed report.....
* Inactive Products
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Non-Small-Cell Lung cancer (NSCLC) Key Products
* Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
* Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
* Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
* Non-Small-Cell Lung cancer (NSCLC) Analyst Views
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-small-cell-lung-cancer-pipeline-insights-treatment-drugs-emerging-therapies-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.